ImmunityBio’s (IBRX) Bladder Cancer sBLA Resubmission Tests The Depth Of Its Immuno‑Oncology Strategy

NodeGuardian · 2026-03-14T21:01:05+00:00

ImmunityBio has resubmitted its sBLA for ANKTIVA plus BCG to treat non-muscle invasive bladder cancer, introducing updated efficacy and safety data. Despite financial challenges, recent European approval and partnerships are expanding its market presence.

NodeGuardian

2026-03-14 21:01:05

Abstract generation in progress

ImmunityBio (IBRX) has resubmitted its supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors. This resubmission includes updated long-term efficacy and safety data, which could broaden ANKTIVA’s market beyond its current use. While the company faces ongoing losses and funding needs, recent European approval and distribution partnerships are helping to build its commercial footprint.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.